Thermo Fisher – Next-Generation Nano, Capillary- & Micro-Flow LC Systems Enhance Productivity & Performance

Thermo Fisher – Principal investigators, laboratories, and proteomics researchers in academia, biopharma, and contract research organizations can now benefit from an all-in-one nano-, capillary- and micro-flow liquid chromatography (LC) system.

Designed for high sensitivity LC-mass spectrometry (LC-MS) applications, technical capabilities and seamless integration with Thermo Scientific PepMap Neo Columns and Thermo Scientific mass-spectrometry portfolio, the new Thermo Scientific Vanquish Neo UHPLC System and Thermo Scientific PepMap Neo Columns help users overcome limitations of existing low-flow LC instruments.

“Low-flow LC users are limited by technical capacity and a high level of expertise required for system operation,” said Kent Davidson, vice president, and general manager, high-performance chromatography solutions, Thermo Fisher Scientific. “The Vanquish Neo UHPLC System and PepMap Neo Columns allow for long-term operation at maximum performance levels without compromise. Enhanced ease-of-use and increased versatility enable users to push science forward.”

Professor Bernhard Kuster, Technical University Munich, said, “The Vanquish Neo UHPLC System will transform how scientists perform proteomics studies by providing the long-term robustness and flow-range versatility required for deep and fast LC-MS profiling of thousands of proteomes, while coupled with PepMap Columns and high-resolution accurate mass (HRAM) systems.”

The new Thermo Scientific Vanquish Neo UHPLC System and Thermo Scientific PepMap Neo Columns deliver application flexibility and robust analytical performance at flow rates from 1 nL/min to 100 µL/min up to 1500 bar. Novice and expert LC-MS users will enjoy accelerated productivity, reduced method overhead time, and long-term operation essential for 24/7 large sample cohort analysis.

Users of the Vanquish Neo UHPLC System and PepMap Neo Columns benefit from:

  • Excellent separation performance, column-to-column reproducibility, and simple operation.
  • Seamless integration with the comprehensive portfolio of Thermo Scientific mass spectrometers.
  • Enhanced quantitation through high-injection volume linearity, precision and accuracy.
  • Negligible system carryover with automated wash routines.
  • System monitoring and control with automated procedures and guided maintenance routines through the Thermo Scientific Vanquish User Interface.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version